Skip Navigation Links
A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
Overall Recruitment Status: Active, currently enrolling
Official Title
A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
Region Sponsors
California - Northern
SWOG Cancer Research Network
Acronym KP IRB No.
Study Type Phase
Other Observational Study with Direct Patient Contact
Study Population Description
This clinical trial examines a financial navigation program in helping patients (and their spouses or partner caregivers, if participating) understand and better manage the financial aspects of cancer care. Cancer patients and their spouse/partner caregivers may be at high risk for financial problems because of the cost of cancer treatment. A financial navigator is a person or team who works with patients and their families to help them reduce stress or hardship related to the cost of cancer treatment. Financial navigators help patients understand their out-of-pocket expenses and what their health insurance plans may cover. Financial navigation may also help patients set up payment plans, find cost-saving methods for treatments, and improve access to healthcare services that the patient needs. Providing financial navigation to patients may help reduce financial worries and improve quality of life.
Detailed Description
Gender Age Limit
Male & Female
Inclusion Criteria
  • Patients must have a diagnosis of a metastatic solid tumor or a hematologic malignancy and must receive anti-cancer treatment (i.e. chemotherapy, hormonal therapy, targeted therapy, biologic therapy, immune therapy, bone marrow transplant). Registration must occur within 180 days after diagnosis of metastatic or stage IV solid tumor or treatment-requiring hematologic malignancy. Patients with indolent hematologic diseases undergoing observation alone are not eligible
  • patients with previously diagnosed hematologic cancers progressed to the point of requiring systemic therapy are eligible, so long as the progression occurred within the previous 180 days. Biopsy confirmation of metastatic disease is not required Patients with recurrent solid tumors will be allowed as long as 1) this is the first presentation of metastatic disease and 2) the diagnosis of the metastasis is at least 180 days (6 months) after the diagnosis date of the previous earlier stage cancer Patients with a history of secondary malignancy are allowed as long as they were not diagnosed within the previous 24 months, are not on active therapy, and are disease-free. Patients with adequately treated basal cell or squamous cell skin cancer, and in situ cervical cancer at any point prior to enrollment are eligible Patients who have started anti-cancer treatment for the current diagnosis must have started within 90 days prior to registration Patients who are planning to start anti-cancer treatment for the current diagnosis must start within (=<) 30 days after registration
Exclusion Criteria
  • Patients may not be enrolled in hospice care at the time of registration Non-spouse/partner caregivers such as friends, adult children, parents, or other relatives living in the same household as the patient are not eligible

Keywords and/or Specific Medical Conditions
  • Oncology (Adult)
KP Clinical Facility
  • All Kaiser Permanente Northern California Medical Centers
Clinical Area
  • Oncology (Adult)

Principal Investigator:
Natalya Greyz
Contact Information:
- Desiree Goldstein
-All Kaiser Permanente Northern California Medical Centers

Do you want to receive
Email Alerts?

Sign Up Here!

Regional Research Sites: